News

Luminoah, Rivanna Medical selected to prestigious med-tech accelerator

Two Charlottesville startups have been selected to MedTech Innovator, a well-known accelerator for medical technology startups.

Luminoah and Rivanna Medical are among 65 companies selected for the Los Angeles-based accelerator’s 2025 cohort. They will participate in a four-month program geared toward accelerating a path to U.S. market success.

Luminoah and Rivanna were both selected in the diagnostic and monitoring category. Luminoah, a former Lighthouse Labs demo day winner that closed a $6 million Series A round in 2023, has developed a mobile feeding tube for patients that collects data. Rivanna offers four products using ultrasound-based imaging technology that it says offer better precision and efficiency to health care professionals.

The MedTech Innovator program will include access to MedTech Innovator’s ecosystem of manufacturers, investors, providers, patients and more. The accelerator’s alumni have collectively brought more than 400 products to market and raised roughly $10 billion in follow-on funding, according to MedTech Innovator.

The 65 selected companies will compete for a share of $800,000 in nondilutive funding. The winners will be selected by audience vote at industry conferences.

MedTech Innovator said it received nearly 1,500 applicants to the program. It ultimately invited 213 companies to pitch at road tour events in Los Angeles, Dublin and College Park, Maryland, and then whittled that field down to 65.

The cohort represents 13 countries and 17 U.S. states.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like